Company intelligence / Profile preview

Molecure S.A. (formerly OncoArendi Therapeutics S.A.)

Poland

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

OATD‑01 has completed preclinical development and entered first-in-human trials in Germany with demonstrated anti-inflammatory and anti-fibrotic effects in animal models. The oncology candidate OATD‑02 is an arginase inhibitor expected to enhance efficacy of cancer immunotherapies; it was in preclinical/IND-enabling studies as of the latest updates. The company has reduced its early-stage pipeline to focus on these two main programs as of April 2025

Therapeutic areas: PulmonologyOncologyImmunologyGastroenterology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

OATD-01

2 more assets in the full pipeline.

Request access →

Partnerships

Exclusive licensing agreement with Ocean Biomedical for selective YKL‑40 inhibitors development/commercializationCollaborations with leading academic institutions

Beyond the preview

Go deeper on Molecure S.A. (formerly OncoArendi Therapeutics S.A.).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecure S.A. (formerly OncoArendi Therapeutics S.A.).

Explore the full profile